Myriad Genetics Presents Second Pivotal Validation Study for RiskScore Test
For women who test negative for hereditary breast cancer mutations, the RiskScore test predicts 5-year and lifetime risk of breast cancer.
Read MoreSearch Results for: genetic testing
GeneSight-Guided Treatment Improves Outcomes for Patients with Major Depression
Study finds improvements in remission, response, and symptoms for patients with major depression whose medication selection was guided by GeneSight testing.
Read MoreMyriad Genetics Signs Definitive Agreement to Acquire Counsyl Inc
The acquisition creates a premier women’s health business unit in the high-growth genetic testing market.
Read MoreGeneSight Testing Improves Outcomes for Patients with Major Depressive Disorder
Compared to treatment as usual, study data showed that patients whose treatment was guided by psychotropic genetic testing experienced a 50% improvement in remission and a 30% improvement in response to treatment.
Read More
Anti-Müllerian Hormone Testing
Anti-Müllerian hormone testing offers a measure of a woman’s ovarian reserve.
Read More